Feed - Buzzberg

12:30
Jul 30 ◎

REGN FY2026 Q2 Watch

Regeneron Pharmaceuticals, Inc. (REGN) FY2026 Q2 Earnings Call

BAYN.DE SNY REGN ▾

Chris Fenimore

Bayesian product royalties and profit share contributed a significant increase to other revenue, indicating underlying strength from the Bayer collaboration's portfolio.

"royalty income from Alaris combined with our share of profits from Arculus totaled $157 million, an increase of 44% versus the prior year."

BAYN.DE WATCH

Dr. Leonard Schleifer

The full repayment of the Sanofi development balance will boost Sanofi collaboration revenue from Q3 onwards, with the company recording its full share of collaboration profits. — A new, higher-margin, recurring profit share kicks in following the repayment.

"productive early discussions with Sanofi to identify potential opportunities for further collaboration, including for several of Regeneron's Depixent follow-on programs."

SNY WATCH

Dr. Leonard Schleifer

Management expresses a bullish outlook on the pipeline, including multiple launches and readouts ahead, while noting moderating growth for Dupixent later in the year.

"Regeneron delivered another strong quarter with total revenues up 17% and non-gap earnings per share up 11% compared to the second quarter of 2025, making our second consecutive quarter of double-digit growth."

REGN WATCH

HIGH

12:30
Apr 29 ◎

REGN FY2026 Q1 Watch

Regeneron Pharmaceuticals, Inc. (REGN) FY2026 Q1 Earnings Call

SNY REGN ▾

Dr. Leonard Schleifer

Sanofi collaboration revenue will step up starting Q3 2026 as the development balance is fully repaid, materially boosting Regeneron's recognized revenue. — This is a significant, durable revenue tailwind for Regeneron from Q3 onwards.

"Maybe it'll give me an opportunity to publicly thank Paul Hudson for all the work he did on Dupixent since 2019..."

SNY WATCH

Ryan Crow

Management tone is positive, highlighting strong Q1 results with double-digit growth and a robust pipeline, with expectations for continued momentum.

"Regeneron is off to a strong start in 2026 with financial results that position us well to continue investing in our pipeline delivering breakthroughs for patients, and driving long-term value for shareholders."

REGN WATCH

HIGH

13:30
Jan 30 ◎

REGN FY2025 Q4 Watch

Regeneron Pharmaceuticals, Inc. (REGN) FY2025 Q4 Earnings Call

BAYRY NVS AMGN BMY RHHBY ▾

Chris Fethmore

Bayer collaboration on Eylea products remains a substantial source of international revenue and profit.

"Total buyer collaboration revenue was $319 million, of which $270 million related to our share of net profits outside the United States."

BAYRY WATCH

Chris Fethmore

Novartis's high sales of Ilaris triggered the highest royalty tier, boosting Regeneron's other revenue.

"Alaris net sales exceeded $1.5 billion in 2025, achieving the top royalty tier of 15% for the first time."

NVS WATCH

Dr. George Yancopoulos

Management highlights a competitor's failure to underscore the uniqueness of Regeneron's antibody discovery technology.

"For example, Amgen, using an inferior humanized mouse approach, tried to make a Dupixent that is starting the same receptor as we did, and their antibody completely failed in all their clinical trials."

AMGN WATCH

Marion McCourt

Libtayo is gaining market share in first-line non-small cell lung cancer against competing PD-1 immunotherapies.

"new patient market share in this setting greater than Optivo, Tecentric, and Infinsi combined."

BMY WATCH

Marion McCourt

Libtayo is gaining share against Roche's Tecentriq in first-line non-small cell lung cancer.

"new patient market share in this setting greater than Optivo, Tecentric, and Infinsi combined."

RHHBY WATCH

Dr. Leonard Schleifer

Management is confident in the near-term outlook, highlighted by strong commercial execution, a late-stage pipeline (including key readouts in melanoma and myasthenia gravis), and multiple planned FDA approvals in 2026.

"Obviously, a busy and ambitious year ahead, one that I'm particularly energized and excited to embark upon."

REGN WATCH

Chris Fethmore

Sanofi's Dupixent royalty recharge is on track to be fully reimbursed by mid-2026, after which the collaboration economics switch to full profit share. — This is a major profitability inflection point for Regeneron, as its profit share will increase materially in the second half of 2026.

"Dupixent's continued strength enabled a rapid reimbursement of the development balance in 2025, which we now expect to be fully reimbursed by mid-2026."

SNY WATCH

HIGH

Feed — Buzzberg